Posts Tagged ‘semaglutide’

This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]

This has been quite a week and the ideas we take home from ObesityWeek 2025 come from both inside and outside of the event in Atlanta. It is a reflection of the fact that the work of cloistered insiders in obesity is and will continue to have large effects in the larger world outside of […]

President Trump held a press event yesterday to issue some very welcome news on coverage and prices for obesity medicines. On prices, they are coming down. In reality, this is an extension of the ongoing trend of downward pressure on these prices that has been in play since the day that semaglutide and tirzepatide launched […]

A new study in Lancet tells us that we need a fundamental reframing of the medical benefits semaglutide can bring to a growing number of people around the world. In the simplest terms, researchers have found that the heart benefits of semaglutide actually have relatively little to do with weight loss. Professor John Deanfield was […]

In the International Journal of Obesity, obesity medicine physician and researcher Caroline Apovian offers a compelling case to favor a prediabetes indication for GLP-1s. She writes: “The approval of a GLP-1 for prediabetes will change the landscape for prevention of T2DM and its complications due to early detection. Currently, most individuals at risk of T2DM […]

Back in March 2024, we welcomed the news of a door opening ever so slightly for Medicare Part D plans to cover GLP-1s in people with obesity and heart disease. So 18 months later, it’s reasonable to ask, how’s that working out for everyone? A new research letter in JAMA gives us an answer, but […]

The emerging contest to dominate the market for oral tablets in obesity treatment became clear this week as news and PR dispatches flowed from EASD in Vienna. Aiming for a Mass Target With understated confidence, Lilly presented and published pivotal phase three data on orforglipron in NEJM. They did not run from the fact that […]

We get a first glimpse of the potential effect of a GLP-1 agonist, semaglutide, in data presented as a late-breaking abstract at the EASD meeting in Vienna this week. This is just a glimpse because it is survey data – self-reported and uncontrolled. With that caveat, though, Timothy Arnaut and colleagues found large reductions in […]

It’s almost funny. Except it’s not. This is deadly serious for people whose entire lives are shaped by obesity – people who need better access to care. The influential Institute for Clinical and Economic Review (ICER) issued a new draft report on the cost effectiveness of semaglutide and tirzepatide. In a nutshell, the report says […]

The short supply, high prices, and despicable insurance restrictions for advanced obesity medicines have created many problems. For example, compounding of these medicines has been and continues to be controversial – for good reasons. Now, FDA is recognizing one of the most pernicious threats to emerge from this situation – sketchy sellers of “research” peptides. […]